Immunic to Present Findings on Vidofludimus Calcium at Toronto Conference

Immunic, Inc., a late-stage biotechnology firm, will present new data on its investigational therapy, vidofludimus calcium, at the MSToronto2026 conference. Four abstracts have been accepted, each examining different aspects of the drug's efficacy in treating multiple sclerosis (MS). The data will be revealed at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto from October 21-23, 2026.

Immunic aims to showcase findings from its phase 2 CALLIPER trial, underscoring long-term benefits of continuous treatment with vidofludimus calcium. Additionally, the presentations will explore the drug's neurological protective qualities and its impacts on immune activities linked to the Epstein-Barr virus (EBV).

These insights contribute to understanding vidofludimus calcium's potential in addressing both inflammatory disease activity and disability progression in MS. The conference promises a platform where Immunic can engage with the broader MS research community.